Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Endometrial Neoplasms 2

Interventions

Cyclophosphamide 910Carboplatin 787pembrolizumab 746Paclitaxel 743Cisplatin 709Bevacizumab 707Gemcitabine 619Docetaxel 580Rituximab 549Radiotherapy 541Dexamethasone 512Nivolumab 489Doxorubicin 445Fluorouracil 392Capecitabine 376Etoposide 358Pemetrexed 337Cytarabine 335Oxaliplatin 333Lenalidomide 328Prednisone 327fludarabine phosphate 316Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 276

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Has results × irosustat × Clear all
NCT00910091 2019-01-30

The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer

Ipsen

Phase 2 Completed
73 enrolled 19 charts
Gynecologic

Endometrial Neoplasms

NCT01251354 2019-01-14

Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy

Ipsen

Phase 2 Terminated
6 enrolled 7 charts
Gynecologic

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡